top of page
Executive Spotlights

ReNAgade Therapeutics Secures $300 Million Series A Funding to Revolutionize RNA Medicine

Cambridge, MA, May 23, 2023 (Business Wire) -- ReNAgade Therapeutics, a cutting-edge company focused on harnessing the full potential of RNA medicines for disease correction, has successfully raised $300 million in a Series A financing round led by MPM BioImpact and F2 Ventures. Built on innovative delivery technologies and an all-RNA platform, ReNAgade aims to overcome limitations in RNA therapeutics by expanding the reach of RNA medicines to previously inaccessible tissues and cells.


Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma

Commentaires


Life Science Headlines
bottom of page